Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy

Urology

Volumn 58, Issue 2 SUPPL. 1, 2001, Pages 56-64

  Grossfeld, Gary D ^a,c   Small, Eric J ^a,b,c   Lubeck, Deborah P ^a,c   Latini, David ^c   Broering, Jeanette M ^c   Carroll, Peter R ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CHLORMADINONE; DIETHYLSTILBESTROL; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

CANCER STAGING; CASTRATION; COGNITIVE DEFECT; CONFERENCE PAPER; DEPRESSION; DISEASE COURSE; FATIGUE; HOT FLUSH; HUMAN; IMPOTENCE; LONG TERM CARE; LYMPH NODE METASTASIS; MALE; METASTASIS; MONOTHERAPY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENT DISEASE; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FINASTERIDE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORCHIECTOMY; POSTOPERATIVE COMPLICATIONS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0034903581     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01243-2     Document Type: Conference Paper

References (46)

1. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
2. Use of second treatment following definitive local therapy for prostate cancer; data from the CaPSURE database
3. Local recurrence after radical prostatectomy; characteristics in size, location, and relationship to prostate-specific antigen and surgical margins
4. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases
5. Management of a positive surgical margin after radical prostatectomy; decision analysis
6. Radiotherapy after radical prostatectomy; treatment outcomes and failure patterns
7. Natural history of progression after PSA elevation following radical prostatectomy
8. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma
9. Paracrine growth stimulation of androgen-responsive Shionogi carcinoma 115 by its autonomous subline (Chiba subline 2)
10. Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes
11. Effects of intermittent androgen suppression on androgen-dependent tumors; apoptosis and serum prostate-specific antigen
12. Hormonal control of growth and progression in tumors of Nb rats and a theory of action
13. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model
14. Intermittent androgen suppression in the management of prostate cancer
15. Intermittent androgen suppression for prostate cancer; rationale and clinical experience
16. Intermittent androgen suppression in the treatment of prostate cancer; a preliminary report
17. Intermittent androgen deprivation for clinically localized prostate cancer; initial experience
18. A pilot study of intermittent androgen deprivation in advanced prostate cancer
19. Long-term follow-up of patients treated with intermittent hormone therapy for advanced prostate cancer
20. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer; a pilot study
21. Intermittent endocrine therapy for advanced prostate cancer
22. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer
23. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer
24. Current status of intermittent androgen suppression in the treatment of prostate cancer
25. Intermittent endocrine therapy of prostate cancer
26. The RAND 36-Item Health Survey 1; 0
27. Quality-of-life outcomes in men treated for localized prostate cancer
28. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues
29. Clinical profile of a new non-steroidal antiandrogen
30. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer
31. Single-agent therapy with bicalutamide; a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma
32. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer
33. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients; results of an Italian Prostate Cancer Project study
34. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer; 6.3 years of followup
35. Finasteride
36. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer
37. Treatment with finasteride following radical prostatectomy for prostate cancer
38. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate
39. Combination finasteride and flutamide in advanced carcinoma of the prostate; effective therapy with minimal side effects
40. Androgen deprivation therapy using finasteride and low dose flutamide to treat PSA failure following therapy for clinically localized adenocarcinoma of the prostate (CaP) [abstract]
41. Combined finasteride and flutamide therapy in men with advanced prostate cancer